Cryptogenic fibrosing alveolitis: have we made any progress?

Area of Science:

• Pulmonology
• Pathology
• Radiology

Background:

• Interstitial lung diseases (ILD) encompass diverse disorders, with cryptogenic fibrosing alveolitis (CFA) being the most prevalent.
• Recent data indicate a higher incidence of CFA (13.2-20.2 per 100,000 population) and an escalating mortality rate.
• The prognosis for CFA remains poor, with a 50% mortality within five years and significant long-term morbidity.

Purpose of the Study:

• To summarize recent advancements in the diagnosis, pathogenesis, and treatment of CFA.
• To review current literature on CFA prevalence, mortality, and diagnostic modalities.
• To highlight the need for collaborative research and multicenter trials for therapeutic and diagnostic advancements.

Main Methods:

• Systematic review of published data.
• Medline database searching for relevant studies on CFA.
• Analysis of diagnostic techniques including open lung biopsy and high-resolution computed tomography (HRCT).

Main Results:

• CFA prevalence is higher than previously thought, with a rising mortality rate.
• High-resolution computed tomography (HRCT) is increasingly used for diagnosis, though its use without tissue confirmation is debated.
• While understanding of pathogenesis has improved, leading to potential new therapies, non-invasive tests require further validation.

Conclusions:

• Significant progress has been made in understanding CFA pathogenesis, paving the way for novel therapeutic strategies.
• New non-invasive tests show promise for patient stratification but need additional evaluation.
• Collaborative multicenter studies are essential to gather sufficient data for robust conclusions on CFA therapies and investigations.